Betmiga prolonged-release tablets contain the active ingredient mirabegron, which is a type of medicine called a selective beta3 adrenoceptor agonist. It is used to treat the symptoms of an overactive bladder (OAB).

Here is a small video intended for OBGYN residents and other residents regarding the medical management for patients with overactive bladder. This video is a collaboration with Dr. Alexandra Dubinskaya.

The video focuses on the 2 main classes of medications: beta-3 agonists and anticholinergics. For anticholinergics, the main ones are oxybutynin and tolterodine. the main side effects of this are dry eyes, tachycardia, constipation, dry mouth.
For beta-3 agonists: the main medications are mirabegron and vibegron. The side effect profiles are significantly less pronounced compared to the anticholinergics. The contraindication for mirabegron is uncontrolled hypertension, since this medication can result in an increase in blood pressure.

Still, OAB is a complex medical condition, which should be first assessed with behavioral changes.

overactive bladder
mirabegron 50 mg
mirabegron tablet uses in hindi
mirabegron 25 mg
mirabegron mechanism of action
mirabegron side effects
urinary incontinence
mirabegron extended release tablets 25 mg tamil
#doctorofmedicine #doctor #cran

Mirabegron is a medication primarily used to treat overactive bladder (OAB) symptoms, such as urinary urgency, frequency, and incontinence. It belongs to a class of drugs known as beta-3 adrenergic receptor agonists. Here's a detailed overview of its pharmacology:

Mechanism of Action
Mirabegron works by selectively stimulating beta-3 adrenergic receptors in the bladder. This leads to relaxation of the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, thereby increasing bladder capacity and reducing symptoms of OAB1.

Pharmacokinetics
Absorption: Mirabegron is rapidly absorbed after oral administration, with peak plasma concentrations reached within 3-4 hours.

Distribution: It has a volume of distribution of approximately 300 liters.

Metabolism: Mirabegron is metabolized in the liver primarily by the cytochrome P450 enzyme system, particularly CYP3A4.

Excretion: The drug and its metabolites are excreted primarily in the urine.

Half-Life: The half-life of mirabegron is about 50 hours, allowing for once-daily dosing.

Clinical Uses
Overactive Bladder (OAB): Treatment of symptoms such as urgency, frequency, and incontinence.

Neurogenic Detrusor Overactivity: Management of bladder symptoms in patients with neurological conditions.

Adverse Effects
Common: Headache, hypertension, nasopharyngitis, and urinary tract infections.

Less Common: Dizziness, constipation, and dry mouth.

Serious: Severe allergic reactions and angioedema (swelling of the deeper layers of the skin).

Drug Interactions
CYP3A4 Inhibitors: Drugs that inhibit CYP3A4 (e.g., ketoconazole, ritonavir) can increase mirabegron levels.

CYP3A4 Inducers: Drugs that induce CYP3A4 (e.g., rifampicin) can decrease mirabegron levels.

Precautions
Hypertension: Monitor blood pressure regularly, especially in patients with a history of hypertension.

Pregnancy and Breastfeeding: Use with caution and only if clearly needed.

Allergies: Inform your healthcare provider if you have any allergies to mirabegron or its components

#Mirabegron

Experience of Mirabegron in the Treatment of Neurogenic Bladder following SCI

Knight S1, Riley C1, Lee F1, Hamid R1

1. Royal National Orthopaedic Hospital

KEYWORDS: Spinal Cord Injury, Overactive Bladder, Incontinence

Following a spinal cord injury (SCI), disruption to the neural pathways to the bladder can result in Neurogenic Lower Urinary Tract Dysfunction (NLUTD). This can lead to reduced bladder capacity, neurogenic detrusor overactivity (NDO), incontinence and potential damage to the upper tracts. The first line treatment is anti-muscarinic medication (AM), however this can be associated with intolerable side effects such as dry mouth, blurred vision and constipation and has been implicated in the development of dementia in older patients. Additionally, AMs are contra-indicated in patients with glaucoma. A ß3 agonist, mirabegron has become available for treatment of OAB and NDO. We have been offering mirabegron (25 or 50 mg) as an alternative to AMs where the patient can no longer take them or as an additional treatment where AMs or botox are not effectively managing NDO. We present the effects of mirabegron treatment on urodynamic parameters in patients with NLTUD following SCI.

General information regarding Myrbetriq (Mirabegron). Content created leveraging AI with the goal of bridging access across communities. Please flag any suggestions or errors in the comment section. Thank you!

Betmiga prolonged-release tablets contain the active ingredient mirabegron, which is a type of medicine called a selective beta3 adrenoceptor agonist. It is used to treat the symptoms of an overactive bladder (OAB).

Comparison between Anticholinergic and Beta-3-adrenergic receptor agonist (Mirabegron) in Overactive Bladder-A systemic review

Wani M1, Masood S1

1. Medway Maritime Hospital

KEYWORDS: Overactive Bladder, Detrusor Overactivity, Pharmacology

This systemic review compared Anticholinergic medications with Beta-3- receptor agonist (Mirabegron) in management of patients with overactive bladder(OAB). The primary aim was to compare efficacy, adverse effects, persistence and adherence and cost effectiveness among these two groups of medications. Other properties considered included tolerability, effect in female OAB, combining two groups of medication in management of OAB.

Myrbetriq, also known as mirabegron, is a medication primarily used to treat the symptoms of an overactive bladder (OAB). It works by relaxing the muscles of the bladder, allowing for increased bladder capacity and reducing the frequent urge to urinate.

Typically, Myrbetriq is prescribed to individuals who experience urinary urgency, urinary frequency, and urge incontinence - all symptoms commonly associated with OAB. It is important to note that Myrbetriq is not a cure for OAB, but rather helps manage the symptoms.

The dosage guidance for Myrbetriq may vary depending on individual circumstances and specific medical conditions. It is crucial to follow the instructions provided by your healthcare professional and not exceed the recommended dosage. Typically, the initial dose is 25 mg once daily, which can be increased to 50 mg if necessary. However, it is essential to consult with your doctor to determine the appropriate dosage for your specific needs.

Like any medication, Myrbetriq may have potential side effects. The most commonly reported side effects include increased blood pressure, headache, urinary tract infection, constipation, and dry mouth. However, it's important to remember that not everyone will experience these side effects, and they may vary in severity. Your healthcare provider can provide a more comprehensive list of potential side effects and help you weigh the risks versus benefits of taking Myrbetriq.

User opinions on Myrbetriq can vary, as experiences with medication can differ from person to person. Some individuals may find significant relief from their OAB symptoms while taking Myrbetriq. They may experience reduced urgency, fewer episodes of incontinence, and an overall improvement in their quality of life. On the other hand, others may not experience the same level of efficacy or may have concerns about potential side effects. It is always a good idea to consult with your doctor and gather information from trusted sources to make an informed decision about taking Myrbetriq.

To summarize, Myrbetriq is a medication commonly used to treat the symptoms of an overactive bladder. It works by relaxing the bladder muscles and reducing urinary urgency and frequency. Dosage guidance should be followed carefully, and potential side effects should be discussed with a healthcare professional. User opinions on Myrbetriq can vary, so it is important to consult with your doctor and gather information to make an informed decision."
-----
"DISCLAIMER: The content of this video is for informational and educational purposes only. It should not be used as a substitute for medical consultation. You should always seek the advice of your doctor or healthcare professional before taking any medication or starting any treatment. Treatments and medications should be prescribed and supervised by a qualified medical doctor only. Individual results may vary and the effectiveness of any treatment mentioned in this video is not guaranteed. Do not self-medicate, if you have any health problems, it is important to seek medical help immediately."

Just as overactive bladder issues and constipation are an issue for patients with multiple sclerosis, mirabegron is a popular medication in the general population for managing these issues. A recent study looked at what impact the treatment could have for these patients' quality of life.

S11 Male Lower Urinary Tract Symptoms 1

Ads supporting Mybetriq or mirabegron as a novel treatment for Overactive Bladder or simply OAB fail to mention its modest effects and excessive price. The cash price for every day of therapy averages approximately $13 for a drug that reduces the frequency of urination from about 11 or 12 episodes a day down to 9 or 10 episodes. Surprisingly an inactive placebo almost appears as effective. Similarly the benefits of Mybetriq for treatment of incontinence barely exceed placebo therapy. While Mybetriq does indeed present a new option for OAB, it lacks dramatic effect. Caution is required since nearly 1 in 20 individuals receiving Mybetriq will experience substantial blood pressure elevation.

Overactive bladder or urinary frequency, urgency of urination, and urinary incontinence, affects millions of American men and women. Now a new drug, Mybetriq, is helpful controlling the symptoms of overactive bladder. The video discusses how the medication works, the side effects, and how to take the medication.